TY - JOUR
T1 - Secondary abnormalities of chromosome 6q in B-cell chronic lymphocytic leukemia
T2 - A sequential study of karyotypic instability in 51 patients
AU - Finn, William G.
AU - Kay, Neil E.
AU - Kroft, Steven H.
AU - Church, Stephanie
AU - Peterson, Lo Ann C.
N1 - Copyright:
Copyright 2007 Elsevier B.V., All rights reserved.
PY - 1998/11
Y1 - 1998/11
N2 - Although karyotypic abnormalities are well documented in B-cell chronic lymphocytic leukemia (B-CLL), few sequential cytogenetic studies have been done. In this study, peripheral blood lymphocytes from fifty-one patients with B-CLL were sequentially karyotyped over a mean interval of 13.8 months (range, one to 51 months). Cytogenetic clones were detected in 33/51 patients (66%) on initial study, including 17 patients with structural abnormalities of chromosome 13q14, and three patients with trisomy 12. Karyotypic evolution was documented in 22/51 patients (43%). The most common secondarily acquired chromosome aberrations were structural abnormalities of the long arm of chromosome 6 involving the region of 6q21-q24 (six patients). Four patients each had acquired structural abnormalities of 1q, 3p, 12q, and 13q. Disease progression, as measured by advance in Rai stage or death from the disease, was observed more often in the clonal evolution group than in the karyotypically stable group (11/22 vs. 5/29; P = 0.017). Patients with secondary abnormalities of 6q had a significantly decreased progression-free survival interval compared with other patients in the study (P = .023). The authors conclude that clonal karyotypic evolution is common in B-CLL, and that clonal evolution correlates with clinical disease progression. Furthermore, the poor outcomes previously attributed to CLL with 6q abnormalities may be related to the clonal acquisition of these abnormalities over time. Future studies should focus on the relevant genetic events underlying the clinical progression observed with karyotypic evolution of B- CLL.
AB - Although karyotypic abnormalities are well documented in B-cell chronic lymphocytic leukemia (B-CLL), few sequential cytogenetic studies have been done. In this study, peripheral blood lymphocytes from fifty-one patients with B-CLL were sequentially karyotyped over a mean interval of 13.8 months (range, one to 51 months). Cytogenetic clones were detected in 33/51 patients (66%) on initial study, including 17 patients with structural abnormalities of chromosome 13q14, and three patients with trisomy 12. Karyotypic evolution was documented in 22/51 patients (43%). The most common secondarily acquired chromosome aberrations were structural abnormalities of the long arm of chromosome 6 involving the region of 6q21-q24 (six patients). Four patients each had acquired structural abnormalities of 1q, 3p, 12q, and 13q. Disease progression, as measured by advance in Rai stage or death from the disease, was observed more often in the clonal evolution group than in the karyotypically stable group (11/22 vs. 5/29; P = 0.017). Patients with secondary abnormalities of 6q had a significantly decreased progression-free survival interval compared with other patients in the study (P = .023). The authors conclude that clonal karyotypic evolution is common in B-CLL, and that clonal evolution correlates with clinical disease progression. Furthermore, the poor outcomes previously attributed to CLL with 6q abnormalities may be related to the clonal acquisition of these abnormalities over time. Future studies should focus on the relevant genetic events underlying the clinical progression observed with karyotypic evolution of B- CLL.
KW - Chromosome 6
KW - Chronic lymphocytic leukemia
KW - Clonal evolution
KW - Cytogenetics
UR - http://www.scopus.com/inward/record.url?scp=0031791801&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031791801&partnerID=8YFLogxK
U2 - 10.1002/(SICI)1096-8652(199811)59:3<223::AID-AJH7>3.0.CO;2-Y
DO - 10.1002/(SICI)1096-8652(199811)59:3<223::AID-AJH7>3.0.CO;2-Y
M3 - Article
C2 - 9798660
AN - SCOPUS:0031791801
SN - 0361-8609
VL - 59
SP - 223
EP - 229
JO - American Journal of Hematology
JF - American Journal of Hematology
IS - 3
ER -